9 Emerging Devices That Will Disrupt Health Care0

Israel 21c predicts that’s Nyxoah’s leadless and minimally invasive neurostimulator for treating sleep apnea will disrupt healthcare.

The company is now gathering additional clinical evidence on Genio, initiating European market development and working toward FDA approval.

OSA is the most common form of sleep apnea, a condition estimated to affect at least 100 million people worldwide.

FREE REPORT
"Learn How To Improve Your Sleeping Patterns and Get Deeper Into Sleep"
Put your best email below to receive instant access to report now!
Leave a Reply